β3和beta 2肾上腺素能受体激动剂和早产:体外子宫松弛效果。
文章的细节
-
引用
复制到剪贴板 -
Dennedy MC,香浓,Gardeil F,莫里森JJ
β3和beta 2肾上腺素能受体激动剂和早产:体外子宫松弛效果。
问卷。2001年6月,108 (6):605 - 9。doi: 10.1111 / j.1471-0528.2001.00147.x。
- PubMed ID
-
11426895 (在PubMed]
- 文摘
-
目的:1。调查的影响选择性β3肾上腺素能受体激动剂,37344年BRL人类怀孕的子宫肌层的收缩性体外。2。比较这些影响与beta 2肾上腺素能受体激动剂、羟苄羟麻黄碱。方法:等长张力记录是在孤立的子宫肌层的表现在生理条件下带活检获得选择性剖腹产。后pre-incubation催产素(10 (9)M),累计增加的影响BRL 37344或羟苄羟麻黄碱(10(8)-10(-3.5)米)在子宫肌层的收缩性。结果表示为日志EC50 (pD2)和平均最大抑制药物化合物的实现。结果:37344年BRL施加浓度依赖松弛剂对子宫肌层的收缩的影响在所有条暴露(pD2 7.26 (0.48) (SEM);平均最大抑制61.98 (4.89%);n = 6]。 Similarly, ritodrine exerted a concentration dependant inhibition of myometrial contractility in all strips exposed [pD2 = 7.40 (0.28); mean maximal inhibition 59.49 (3.97%); n = 6]. There was no significant difference between calculated pD2 values (P = 0.65) or mean maximal inhibition achieved (P = 0.79). CONCLUSIONS: The beta-3 adrenoreceptor agonist BRL 37344 induced relaxation of human myometrial contractions with similar potency to that of the most commonly used tocolytic agent ritodrine. This raises the possibility that the novel beta-3 adrenoreceptor agonists may have potential as therapeutic agents for human preterm labour. In view of their reported reduced cardiovascular side effects their potential clinical use requires further evaluation.